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Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by
a progressive decline in lung function due to airflow limitation, mainly related to IL-1β-induced
inflammation. We have hypothesized that single nucleotide polymorphisms (SNPs) in NLRP genes,
coding for key regulators of IL-1β, are associated with pathogenesis and clinical phenotypes of COPD.
We recruited 704 COPD individuals and 1238 healthy controls for this study. Twenty non-synonymous
SNPs in 10 different NLRP genes were genotyped. Genetic associations were estimated using logistic
regression, adjusting for age, gender, and smoking history. The impact of genotypes on patients’
overall survival was analyzed with the Kaplan–Meier method with the log-rank test. Serum IL-1β
concentration was determined by high sensitivity assay and expression analysis was done by RT-PCR.
Decreased lung function, measured by a forced expiratory volume in 1 s (FEV1% predicted), was
significantly associated with the minor allele genotypes (AT + TT) of NLRP1 rs12150220 (p = 0.0002).
The same rs12150220 genotypes exhibited a higher level of serum IL-1β compared to the AA genotype
(p = 0.027) in COPD patients. NLRP8 rs306481 minor allele genotypes (AG + AA) were more common
in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition of group A (p= 0.0083).
Polymorphisms in NLRP1 (rs12150220; OR = 0.55, p = 0.03) and NLRP4 (rs12462372; OR = 0.36,
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p = 0.03) were only nominally associated with COPD risk. In conclusion, coding polymorphisms in
NLRP1 rs12150220 show an association with COPD disease severity, indicating that the fine-tuning of
the NLRP1 inflammasome could be important in maintaining lung tissue integrity and treating the
chronic inflammation of airways.
Keywords: COPD; NLRP; polymorphism; FEV1; FEV1/FVC; GOLD; serum IL-1β
1. Introduction
Chronic obstructive pulmonary disease (COPD) is currently a leading cause of death [1]. The World
Health Organization (WHO) predicts that by the year 2030 COPD will be the third leading cause of
death in the world [2]. COPD is a chronic inflammatory disease leading to structural abnormalities
in the airways, and it is associated with exposure to noxious particles, like cigarette smoke [3].
The disease is characterized by a progressive and irreversible decline in lung function due to airflow
obstruction and parenchyma destruction [4]. The genetic basis of innate immune response is now a
well-established contributor in disease pathogenesis, since only 15–20% of smokers develop COPD,
and chronic inflammation persists even after smoking cessation [5]. COPD is associated with different
comorbidities that affect the clinical phenotype of the disease, its course, and outcome [6]. The causal
relationship between comorbidities and COPD remains unclear [7]. It is known that the clinical course,
prognosis, and overall survival of COPD patients are all influenced by comorbidities, many of which are
accompanied by systemic inflammation [8]. The respiratory innate immune cells constantly respond to
a broad spectra of inhaled microbes and air pollutants. They sense potential threats or ‘dangers’ through
the expression of the receptors known as pattern-recognition receptors (PRRs). PRRs play a role in the
recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) [9]. Upon the recognition of PAMPs or DAMPs, PRRs elicit the activation of the
innate immune response to eliminate the source of danger and restore tissue homeostasis. Deficient
mucosal immunity can cause serious infections, while the persistent exposure of the respiratory
epithelium to environmental factors contributes to pulmonary diseases, like COPD. Nod-like receptors
(NLRs) are PRRs that can recognize both PAMPs and DAMPs. NLRPs, which are members of the NLR
family, comprise a group of 14 proteins, contributing to both the inflammatory and tissue remodeling
processes [10]. NLRPs can be activated by a broad range of stimuli, from bacterial products to a
number of stress- and damage-associated signals, culminating in inflammasome formation and the
caspase-1 proteolytic cleavage of the IL-1β precursor [11]. Generally, five main inflammasomes are
identified: NLRP1, NLRC4, RIG-1, AIM2, and NLRP3. When activated, upon exposure to structurally
different PAMPs or DAMPs, they act as scaffolds to form active protein complexes together with an
adaptor protein, namely, an apoptosis-associated speck-like protein containing a caspase recruitment
domain (ASC), and pro-caspase-1 [12]. In different COPD models, many studies have demonstrated
that IL-1β significantly contributes to airway inflammation and emphysema, where both stabile and
exacerbating COPD IL-1β secretion is increased [13]. Also, IL-1β induces the secretion of IL-8 and
IL-6, two cytokines that promote neutrophil recruitment, a process that significantly contributes to
neutrophilic airway inflammation [14]. However, the relative contribution of different inflammasomes
in inducing IL-1β responses and their roles in pathogenesis of COPD are still elusive [15]. Hence, it is
conceivable that the genetic variability of the key regulators of IL-1β, i.e., NLRPs, could be associated
with COPD and its different clinical phenotypes. The aim of this study was to perform a genetic
association study on the basis of COPD in a case-control cohort and its disease conditions in the
case-only cohort, in the context of the single nucleotide polymorphism (SNP) frequency of the NLRP
genes. The genetic background was examined in the context of the single nucleotide polymorphism
(SNP) frequency of the NLRP genes.
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2. Materials and Methods
2.1. Study Population
The demographic characteristics of the study population are shown in Table 1 and the clinical
characteristics of the COPD patients are shown in Table 2. The diseased population was recruited
by the Department for Respiratory Diseases, in the Clinical Hospital Centre in Zagreb, and the
Department for Pulmonology, Clinical Hospital Centre Osijek, Croatia. Genotyping was conducted
on 527 COPD cases, together with 1238 healthy controls, which were collected at the Department of
Transfusion Medicine, Zagreb, Croatia. COPD diagnosis and its stage were defined according to the
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Update 2017). Spirometry was
performed according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria.
A post-bronchodilator FEV1/FVC ratio less than 70 was considered as a diagnosis of airflow limitation.
Phenotype evaluation was done by pulmonary function tests, with the clinical data obtained for three
cardinal symptoms (dyspnea, chronic cough and sputum production), the annual exacerbation rate,
and performance status. Patient assessment included their past medical history, covering significant
comorbidities, exposure to risk factors, physical examination, and smoking status. Age at onset was
also registered. The follow-up data used for overall survival (OS) were obtained from medical records.
Survival data were obtained for 525 patients, of whom 81 died during the follow-up period. The median
follow-up time of the patients was 81 months (range 1–451 months). OS time was measured from the
date of diagnosis to the time of death by any cause. Comorbidity was defined as the presence of one
or more distinct disorders or diseases in addition to COPD. The control group of healthy volunteers,
recruited during the regular blood donation process by the Department of Transfusion Medicine,
Zagreb, represents the general healthy population characterized by good basic health status. Patients
recruited for serum and RNA isolation needed to meet an additional inclusion criterion. For the COPD
cohort (N = 100), this criterion was the stable state of the disease, defined as having no symptoms that
could be correlated with exacerbation over at least 4–6 weeks, while for the healthy control subjects
(N = 100), the exclusion criterion was a history of acute pulmonary infection or any other infection in
the last 6 weeks before assessment. This study was performed in accordance with the Declaration of
Helsinki. The study was approved by the ethical committees of University Hospital Centers Zagreb
and Osijek and Croatian Institute of Transfusion Medicine. All participants provided written informed
consent to participate in this study.
Table 1. Demographic characteristics of the tested population.
Characteristic Chronic Obstructive PulmonaryDisease (COPD) Patients Healthy Controls
Sex
Male 487 (69.2) 1116 (87.3)
Female 217 (30.8) 163 (12.7)
Age, year, median (SD, minimum and maximum) 61 (8.25; 33–85) 38 (12; 16–66)
Smoking History
Non-smoker 56 (8.1) 954 (74.4)
Former 424 (61.5) 3 (0.2)
Active 209 (30.3) 325 (25.3)
Missing data 15 (2.1) 1 (0.1)
Data are presented as number (%).
Table 2. The clinical characteristics in the cohort of COPD patients and the frequency of the comorbidities.
Characteristic COPD Patients
Smoking, pack-year, median (range) 40 (0.8–160)
GOLD classification
A 172 (26.1)
B 171 (25.9)
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Table 2. Cont.
Characteristic COPD Patients
C 172 (26.1)
D 145 (21.9)
FEV1/FVC, %, mean (SD) 56.66 (21.6)
FEV1, %, mean (SD) 55.13 (22.0)
Cough 597/704 (84.8)
mMRC 1
0 59 (8.4)
1 168 (23.9)
2 238 (33.9)
3 166 (23.6)
4 72 (10.2)
Annual exacerbation rate
0 234 (33.2)
2 346 (49.1)
>2 124 (17.6)
Hospital admission 276 (39.2)
Number of comorbidities
0 117 (16.6)
1 203 (28.8)
2 201 (28.6)
≥3 183 (26)
Comorbidities
Pulmonary hypertension 49 (7%)
Arterial hypertension 353 (50.1%)
Lung cancer 72 (10.2%)
Cardiovascular diseases 196 (27.8%)
Diabetes mellitus 100 (14.2%)
Extrapulmonary neoplasms 63 (8.9%)
Chronic gastritis /GERD 71 (10.1%)
Chronic kidney disease 29 (4.1%)
Osteoporosis 35 (5%)
Psychiatric disorders 37 (5.3%)
Data are presented as number (%). 1 0, breathless with strenuous exercise; 1, shortness of breath when hurrying on
the level or walking up a slight hill; 2, shortness of breath when walking its own pace on the level; 3, shortness of
breath after walking about 100 m; 4, breathless when dressing. GOLD, Global Initiative for Chronic Obstructive
Lung Disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; mMRC, modified Medical
Research Council dyspnea; GERD, gastroesophageal reflux disease.
2.2. Gene/SNP Selection and Genotyping
The gene selection criterion was based on the hypothesis that the genetic diversity of NLRPs
is implicated in the dysregulated activation/regulation of respiratory inflammation. Twenty SNPs
located in 10 NLRP genes were tested (Table 3). All tested SNPs are missense variants, and they are
located in the coding regions, with a minor allele frequency higher than 1% (based on the dbSNP
database (NCBI, Bethesda, MD, USA) (http://www.ncbi.nlm.nih.gov/snp), and only 1 SNP per linkage
block was selected for genotyping. Out of the 20 selected SNPs, 15 were located in the specified
NLRP domains (1 in FIIND, 5 in LRR and 9 in NACHT domain), while the others were located in the
linker domains of the proteins (Figure 1). More details on the selection criteria can be found in [16].
The deleteriousness of the amino acid changes were predicted using SIFT (http://sift.jcvi.org/) and
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/). Genotyping was performed using the previously
published protocol [17].
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Table 3. List of the single nucleotide polymorphisms (SNPs) analyzed in the study, minor allele frequency,
and the functional consequence according to SIFT and PolyPhen, respectively.
GENE SNP MAF Amino AcidChange Domain SIFT PolyPhen
NLRP1 rs12150220_A_T 0.231 (T) L155H Deleterious 1 possibly damaging 1
NLRP1 rs35596958_T_C 0.046 (C) M1119V FIIND tolerated benign
NLRP2 rs1043673_C_A 0.416 (A) A1052E tolerated benign
NLRP3 rs35829419_C_A 0.022 (A) Q705K tolerated benign
NLRP4 rs441827_C_T 0.383 (T) A144T tolerated benign
NLRP4 rs12462372_G_A 0.059 (A) R708H LRR tolerated benign/probablydamaging 2
NLRP4 rs17857373_G_C 0.013 (C) P390Q NACHT tolerated benign
NLRP4 rs302453_A_T 0.219 (T) Q925L LRR tolerated benign
NLRP5 rs10409555_G_A 0.258 (A) V1181I LRR tolerated benign
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Table 3. Cont.
GENE SNP MAF Amino AcidChange Domain SIFT PolyPhen
NLRP5 rs16986899_T_C 0.265 (C) M912T LRR tolerated benign
NLRP5 rs471979_G_C 0.125 (C) M459I NACHT tolerated benign
NLRP6 rs56159585_T_A 0.299 (A) Y361F NACHT tolerated benign
NLRP6 rs77447196_C_G 0.217 (G) P244A NACHT tolerated benign
NLRP8 rs306457_C_G 0.275 (G) Stop lost tolerated benign
NLRP8 rs306481_G_A 0.494 (A) K937R LRR tolerated benign
NLRP11 rs12461110_G_A 0.243 (A) P438L NACHT tolerated
benign/possibly
damaging/probably
damaging 3
NLRP11 rs299163_A_C 0.047 (C) A188S NACHT tolerated benign
NLRP12 rs34436714_A_C 0.267 (C) G39V NACHT deleterious 1 benign
NLRP12 rs34971363_G_C 0.051 (C) F402L NACHT deleterious 1 probably damaging 2
NLRP13 rs303997_C_T 0.335 (T) Q247R NACHT deleterious 1 benign
1 In all transcripts. 2 Depending on transcript (probably damaging in one of the protein coding transcripts).
3 Depending on transcript (possible damaging in one of the protein coding transcripts; probably damaging in two
nonsense mediated decay transcripts). MAF, minor allele frequency in Croatian population; SIFT, Sorting Intolerant
from Tolerant; PolyPhen, Polymorphism Phenotyping.
2.3. Gene Expression Analyses
The gene expression analyses were performed on RNA samples isolated from peripheral blood
mononuclear cells (PBMCs) from COPD patients and healthy donors, as well as from the human lung
fibroblast cell line (WI38?; obtained from ATCC) using TaqMan Gene expression assays (Thermo Fisher)
for the NLRP1, NLRP4, and NLRP8 genes. The WI38 cell line was selected for the study because
fibroblasts are believed to be the major cells responsible for the production and maintenance of the
extracellular matrix, and fibroblasts from individuals with COPD have a reduced capability to sustain
tissue repair [18]. The total RNA, from blood, was extracted using Trizol. A RNeasy Mini Kit (Qiagen)
was used for RNA extraction from human lung fibroblast WI38. Reverse transcription was done with a
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The analyses were performed
in triplicate using the 7300 Real-time PCR System (Applied Biosystems).
2.4. Serum IL-1β Concentration
Concentrations of IL-1β in the sera of COPD patients and healthy donors were measured using a
ProcartaPlex High Sensitivity Assay, with a corresponding IL-1b bead set (Thermo Fisher Scientific,
Waltman, MA, USA), according to manufacturer’s recommendation. Briefly, 50 µL of antibody-coated
magnetic beads were added per well into a 96-well plate and washed. Afterwards, 25 µL of samples
or standards were added to a 25 µL universal assay buffer, and the plate was incubated for 30 min
at room temperature (RT) and overnight at 4 ◦C, with shaking. After the washing steps, 25 µL of
detection antibodies were added to the wells and the plate was incubated for 30 min at RT, with shaking.
After the washing, 50 µL of a streptavidin-phycoerythrin conjugate was added to the wells. After the
incubation and washing steps, 50 µL of amplification reagent 1 was added to the wells, and the plate
was incubated for 30 min at RT, with shaking. Then, amplification reagent 2 (50 µL) was added to
the wells, and following the incubation and washing steps, the beads were resuspended in a 120 µL
reading buffer and analyzed by use of a Luminex 200 instrument. The concentration of IL-1β was
determined by interpolation from a standard curve using the xPONENT software package (Luminex,
Austin, TX, USA).
2.5. Statistical Analysis
Associations between the genotyped markers and disease were estimated as odds ratios (ORs)
with 95% confidence intervals (CIs) using logistic regression. These were adjusted for gender, age,
and smoking history. The associations were calculated for dominant and codominant models. The χ2
test was used to assess the distribution and association of categorical variables. Since the continuous
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variables did not show a normal distribution, which was tested with the D’Agostino-Pearson test, the
non-parametric Mann–Whitney test, and the non-parametric Kruskall–Wallis test, with a post-hoc test
according to Conover, which was used to determine if there were statistically significant differences
among the genotypes. The median was used as a cut-off value to dichotomize continuous variables.
p values below 0.0025 were considered statistically significant (Bonferroni correction), while the
nominal association was assigned to p values below 0.05. For assessing the influence of genotypes
on patients’ overall survival, the Kaplan–Meier method was used for calculating survival curves,
which were compared by the log-rank test. Two-tailed p-values <0.05 were considered statistically
significant, while for the pairwise comparison of GOLD status, the Bonferroni correction was applied.
The statistical analyses were performed using MedCalc version 18.2.1 (MedCalc Software, Ostend,
Belgium) and SAS, software version 9.2 (SAS Institute, Heidelberg, Germany).
3. Results
3.1. Association of the NLRP Coding Variants with COPD Risk and Disease Severity
We genotyped 20 SNPs located in 10 different NLRP genes (Table 1). Logistic regression analysis,
adjusted for age, gender, and smoking history, indicated only a nominal association with COPD risk
for two SNPs in dominant model: NLRP1 SNP rs12150220_AT (A/T OR = 0.54, p = 0.03; T/T OR = 0.59,
p = 0.17; A/T + T/T OR = 0.55, p = 0.03) and NLRP4 SNP rs12462372_AG (A/G OR = 0.36, p = 0.03; A/A
OR = 0.29, p = 0.77; A/G + A/A OR = 0.36, p = 0.03), suggesting that there is no association between the
tested SNPs and COPD risk (Table 4). However, when we performed an association study of the NLRP
SNPs and disease conditions that are important predictors of COPD severity and disease outcome,
such as the GOLD groups (ABCD groups), the predicted FEV1%, and FEV1/FVC ratio (Tiffeneau index),
we found that the SNPs located in the NLRP1 and NLRP8 genes were associated with GOLD, FEV1%,
and the FEV1/FVC ratio. We found a significant difference between the frequencies of the genotypes
of NLRP8 polymorphism rs306481 (p = 0.0002; chi-square test) in the GOLD groups (ABCD), while
NLRP1 rs12150220 association was of borderline significance (p = 0.049) (Table S1). Pairwise analysis
showed that the most significant difference in the distribution of the genotypes was for the NLRP8 SNP
rs306481 between GOLD groups A and D (p = 0.0001). The subgroup analysis showed that genotypes
harboring allele A (AG+AA) were more frequent among patients in GOLD group A, while genotype
GG (p = 0.0083) was more frequent among patients in GOLD group D (Figure 2A). This suggests that
the minor allele A may be protective, and that the major allele G is a risk allele for a more severe disease.
We also detected that the FEV1% predicted values were differently distributed between the NLRP1
rs12150220 genotypes (p = 0.00014) and the post-hoc analysis, showing that genotypes harboring minor
allele T (AT+TT) were associated with a lower FEV1% (p = 0.0002) (Figure 2B). Finally, we detected
that FEV1/FVC ratio was differently distributed between the genotypes of the same polymorphism
(rs12150220) (p = 0.0083). The post-hoc analysis (Mann–Whitney test) showed a significant association
between the homozygous genotype rs12150220_AA (major allele) with higher values of the FEV1/FVC
ratio, compared to genotypes harboring minor allele (AT+TT) (p = 0.0083) (Figure 2C). We did not find
any association between the NLRP polymorphisms and overall survival (Supplementary Figure S1).
Table 4. Genotype frequencies of tested single nucleotide polymorphisms (SNPs) in the COPD cases and
the control population and their associations with COPD adjusted for age, gender and smoking status.
Adjusted for Age/Gender/Smoking
SNP Genotype COPD Cases Controls OR (95%CI 2) 1 p
rs12150220 A/A 113 (29.20%) 307 (24.64%) 1.00
A/T 190 (49.10%) 642 (51.52%) 0.54 (0.31–0.95) 0.03 *
T/T 84 (21.71%) 297 (23.84%) 0.59 (0.28–1.26) 0.17
A/T+T/T 274 (70.80%) 939 (75.36%) 0.55 (0.32–0.95) 0.03 *
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Table 4. Cont.
Adjusted for Age/Gender/Smoking
SNP Genotype COPD Cases Controls OR (95%CI 2) 1 p
rs35596958 T/T 335 (86.79%) 1086 (87.16%) 1.00
C/T 49 (12.69%) 160 (12.84%) 0.86 (0.42–1.78) 0.69
C/C 2 (0.52%) 0 (0.00%) - -
rs1043673 C/C 152 (39.79%) 471 (37.83%) 1.00
A/C 177 (46.34%) 589 (47.31%) 1.13 (0.65–1.95) 0.67
A/A 53 (13.87%) 185 (14.86%) 0.92 (0.42–2.01) 0.83
rs35829419 C/C 346 (89.41%) 1141 (91.35%) 1.00
A/C 39 (10.08%) 107 (8.57%) 1.07 (0.44–2.58) 0.88
A/A 2 (0.52%) 1 (0.08%) - 0.80
rs441827 C/C 155 (40.16%) 464 (37.09%) 1.00
T/C 168 (43.52%) 598 (47.80%) 0.82 (0.47–1.44) 0.49
T/T 63 (16.32%) 189 (15.11%) 1.02 (0.50–2.10) 0.95
rs12462372 G/G 354 (91.00%) 1092 (88.21%) 1.00
A/G 34 (8.74%) 143 (11.55%) 0.36 (0.15–0.90) 0.03 *
A/A 1 (0.26%) 3 (0.24%) 0.29 (0.00–949.77) 0.77
A/G+A/A 35 (9.00%) 146 (11.79%) 0.36 (0.15–0.90) 0.03 *
rs17857373 G/G 359 (92.76%) 1162 (92.89%) 1.00
C/G 26 (6.72%) 88 (7.03%) 0.96 (0.34–2.69) 0.94
C/C 2 (0.52%) 1 (0.08%) - -
rs302453 A/A 215 (55.41%) 681 (54.83%) 1.00
A/T 159 (40.98%) 471 (37.92%) 1.59 (0.94–2.71) 0.09
T/T 14 (3.61%) 90 (7.25%) 0.31 (0.09–0.99) 0.05
rs10409555 G/G 212 (54.78%) 664 (53.12%) 1.00
A/G 142 (36.69%) 495 (39.60%) 0.59 (0.34–1.03) 0.06
A/A 33 (8.53%) 91 (7.28%) 1.75 (0.73–4.20) 0.21
rs16986899 T/T 268 (69.79%) 857 (68.89%) 1.00
C/T 104 (27.08%) 348 (27.97%) 1.17 (0.66–2.07) 0.60
C/C 12 (3.13%) 39 (3.14%) 0.77 (0.19–3.06) 0.71
rs471979 G/G 293 (79.62%) 962 (80.37%) 1.00
C/G 68 (18.48%) 219 (18.30%) 0.72 (0.36–1.43) 0.35
C/C 7 (1.90%) 16 (1.34%) 4.14 (0.93–18.49) 0.06
rs56159585 T/T 320 (82.69%) 969 (79.23%) 1.00
A/T 61 (15.76%) 238 (19.46%) 0.54 (0.27–1.07) 0.08
A/A 6 (1.55%) 16 (1.31%) 0.11 (0.00–4.43) 0.24
rs77447196 C/C 265 (68.48%) 823 (66.42%) 1.00
C/G 117 (30.23%) 363 (29.30%) 0.72 (0.40–1.29) 0.27
G/G 5 (1.29%) 53 (4.28%) 0.38 (0.07–2.12) 0.27
rs306457 C/C 227 (58.81%) 757 (60.71%) 1.00
C/G 134 (34.72%) 413 (33.12%) 1.08 (0.63–1.85) 0.77
G/G 25 (6.48%) 77 (6.17%) 0.39 (0.12–1.30) 0.12
rs306481 G/G 142 (36.50%) 405 (32.58%) 1.00
A/G 190 (48.84%) 604 (48.59%) 0.95 (0.55–1.65) 0.86
A/A 57 (14.65%) 234 (18.83%) 0.60 (0.27–1.33) 0.21
rs12461110 G/G 158 (41.15%) 501 (40.14%) 1.00
A/G 160 (41.67%) 568 (45.51%) 0.76 (0.44–1.33) 0.34
A/A 66 (17.19%) 179 (14.34%) 1.26 (0.61–2.61) 0.54
rs299163 A/A 349 (89.95%) 1066 (85.76%) 1.00
A/C 38 (9.79%) 172 (13.84%) 0.93 (0.46–1.90) 0.85
C/C 1 (0.26%) 5 (0.40%) 0.02 (0.00–11710.48) 0.57
rs34436714 C/C 251 (65.88%) 771 (61.98%) 1.00
A/C 117 (30.71%) 407 (32.72%) 0.62 (0.35–1.08) 0.09
A/A 13 (3.41%) 66 (5.31%) 0.40 (0.11–1.43) 0.16
rs34971363 G/G 325 (83.98%) 1049 (83.79%) 1.00
C/G 60 (15.50%) 191 (15.26%) 1.26 (0.62–2.58) 0.52
C/C 2 (0.52%) 12 (0.96%) 0.41 (0.01–31.83) 0.69
Genes 2019, 10, 783 9 of 14
Table 4. Cont.
Adjusted for Age/Gender/Smoking
SNP Genotype COPD Cases Controls OR (95%CI 2) 1 p
rs303997 C/C 124 (32.12%) 418 (33.63%) 1.00
C/T 201 (52.07%) 630 (50.68%) 1.13 (0.65–1.98) 0.67
T/T 61 (15.80%) 195 (15.69%) 1.09 (0.51–2.30) 0.83
* p values <0.05 1 OR, odds ratio 2 CI, confidence interval.
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3.2. NLRP1 is Expressed in Human PBMCs and Lung Fibroblasts
We quantified mRNA levels in the immune cells separated from peripheral blood (PBMCs) from
4 COPD patients and the human lung fibroblast cell line (WI38). ∆CT values (normalized to GAPDH
CT values), which should be reverse-proportional to mRNA expression, indicated that the PBMCs
and the WI38 cell line express the NLRP1 gene. The detected CT values were 28–36 cycles (mean
CT = 30 cycles), indicating moderate expression. In the case of NLRP4, only a minimal expression level
was observed, while in case of NLRP8, we did not detect any expression in any of the tested samples
(CT values were detected only above 40 cycles) (Figure 3A). In order to see if specific genotypes could
be associated with a different expression level of NLRP1 in PBMCs, 15 cDNA samples from COPD and
equal number of healthy donors were analyzed. The results of this analysis indicated that there were
no differences in the expression levels of NLRP1 between healthy and COPD samples, and also that the
expression was not influenced by different rs12150220 genotypes (Figure 3B).
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IL-1β concentration. (A) Real-time PCR analysis of NLRP1, NLRP4 and NLRP8 mRNA was performed
on cDNA sa ples from COPD atients (N = 4) and WI38 cell line (human lung fibroblasts). Total RNA
was isolated either from peripheral blood mononuclear cells (PBMC) r cell line, and reverse-transcribed
to cDNA. GAPDH was used as a reference or endogenous control. For quantification see Materials and
Methods. (B) Real-time PCR analysis of NLRP1 mRNA expression levels. The expression analysis was
performed on 15 cDNA samples from heathy individuals and equal number of COPD patients (RNA
was isolated from PBMC). GAPDH was included as a reference or endogenous control. ∆CT values of
NLRP1 were normalized to GAPDH CT values and ∆CT is shown on the graph. Each col mn represents
the average alue of ∆CT of 5 individuals with the given gen type (A/A, A/T or T/T). The experiment
was conducted two times in duplicates. (C) Conce tration of the serum IL-1β i healthy and COPD
individuals. IL-1β concentration was determined in the plasma samples separated from the healthy
donors (N76) and the individuals with diagnosed COPD (N = 100) (NLRP1 genotype (rs12150220)
was known for each sample). Analysis was performed with a ProcartaPlex High Sensitivity Assay,
according to manufactures protocol, which can be found in the Materials and Methods section. (D) The
concentration of serum IL-1β is related to rs12150220. The relationship betwee IL-1β c ncentration
and NLRP1 (rs12150220) genotypes AA (N = 24) vs. AT+TT (N = 76) in the COPD serum samples.
AT and TT genotypes carriers had higher IL-1β levels compared to the AA genotype carriers.
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3.3. Serum Concentration of the IL-1β in the COPD Patients is Associated with NLRP1 rs12150220 Genotype
The proinflammatory cytokine interleukin IL-1β is the key mediator of neutrophilic airway
inflammation in COPD. As NLRPs are key regulators of IL-1β, we wanted to examine if the serum
level of IL-1β could be associated with NLRP1 (rs12150220) genotypes. First, we confirmed that serum
IL-1β is significantly elevated in COPD patients in comparison to healthy donors (nonparametric
Mann–Whitney test; p < 0.0001, Figure 3C). Due to the almost undetectable level of the serum IL-1β
in healthy donors, they were excluded from further analyses. Next, we compared the frequency of
minor allele genotypes (AT+TT) and the major allele (AA) genotype with serum IL-1β and found
that major allele homozygosity was associated with lower IL-1β concentration (nonparametric t-Test;
p = 0.03, Figure 3D). In conclusion, it seems that the presence of the minor allele could be associated
with, to some extent, elevated levels of serum IL-1β.
4. Discussion
The case-control and case-only association studies identified three coding SNPs, so far not
analyzed in this context, that were associated with COPD disease severity and IL-1β concentration in
the serum: NLRP1 (rs12150220, L155H), NLRP4 (rs12462372, R708H) and NLRP8 (rs306481, K937R).
Expression analysis showed that only the NLRP1 gene exhibits moderate expression levels in both
the PBMCs of COPD patients and the WI38 cell line. Therefore, the functional significance of the
NLRP4 and NLRP8 polymorphisms in our case is not clear. In vitro studies, performed by others,
have shown that NLRP4 is a negative regulator of type I interferon activity [19] and autophagy during
A streptococcal infection [20]. However, it is hard to predict any functional consequence of NLRP4 in
the lung, due to the fact that rs12462372 was also predicted to be tolerated and benign by SIFT and
PolyPhen (Table 2). The same was true for NLRP8 rs306481, which we found to correlate with the
GOLD groups. The functional consequences of this finding are difficult to comment on, since there
is a lack of published data on NLRP8 function, probably due to the fact that its expression is lost in
rodents [21]. Therefore, our report, based on a genetic association study, that the minor allele A could
be considered as protective, should be interpreted with caution.
For us, the most interesting finding of this study was thatNLRP1 rs12150220 exhibited a statistically
significant association with lung function, where minor allele carriers had a decreased FEV1% and
FEV1/FVC ratio, together with, to some extent, elevated serum IL-1β-clinical conditions, which have
been strongly correlated with worse COPD prognosis [22]. The fact that we did not find any association
between the genotypes and overall survival does not contradict our findings regarding lung function
and IL-1β levels, because the effects of individual SNPs are usually small compared to comorbidities
or other strong prognostic markers. On the other hand, our results may indicate that the NLRP1 SNP
rs12150220 may, indirectly, affect survival by affecting COPD phenotypes. It is worth mentioning that
more than 54% of COPD patients recruited in this study have more than two comorbidities, while
more that 28% have one. The presence of different comorbidities significantly impacts patients’ quality
of life, exacerbation frequency, survival, and, in general, clinical outcomes [23]. Many comorbidities
that result from the chronic inflammatory state are present in COPD, and it is possible that persistent
low-grade systemic inflammation may be the link between COPD and comorbidities [24]. However,
the precise mechanisms of these processes are yet to be defined. It has been shown that obesity,
which is found to be more frequent in the COPD group, affects patients’ clinical manifestations and
quality of life, possibly by contributing to the phenotype group characterized by increased systemic
inflammation [25].
The innate immune response in the lungs, orchestrated by NLRPs, is the key step in sensing
infection, tissue damage, and different types of tissue integrity disturbance [26]. Defects in the NLRP1
inflammasome pathway have been linked to different pulmonary diseased conditions. Li et al. has
shown that the activation of the NLRP1 and NLRP3 inflammasome pathways may contribute to
pulmonary fibrosis caused by latent MCMV infection in mice [27]. Crovella et al. have investigated how
the genetic variability of inflammasome encoding genes impacts the formation of asbestos bodies (Abs)
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in lung parenchyma, showing that the NLRP1rs12150220 missense variant significantly correlates with
the number of ABs in malignant pleural mesothelioma patients [28]. Leal et al. found that the NLRP1
gain-of-function variants rs11651270, rs12150220, and rs2670660 are significantly associated to asthma,
while rs11651270 and rs2670660 are associated with asthma severity and the total IgE level in asthmatic
children [29]. Interestingly, it has also been shown that different autoimmune diseases, like vitiligo and
systematic lupus erythematosus (SLE) are associated with defects in NLRP1 [30]. L155H (rs12150220)
is located in the linker region, between PYD and NACHT domains of the NLRP1 receptor, and was
predicted to be deleterious, as reported by Levandowski et al. [31]. They have shown that L155H
mutation is associated with autoimmunity and increased IL-1β processing, which also agrees with our
results. Cultured L155H/L155H peripheral blood monocytes, in unstimulated conditions, processed
significantly greater amount of the pro-IL-1β to mature IL-1β, compared to wild type. The precise
mechanism by which L155H affects inflammasome activation is not known. It is very likely that L155H
haplotype is associated with the increased auto-proteolytic activation of L155H-NLRP1, resulting in the
systemic activation of caspase-1 and increased IL-1β processing. However, beside IL-1β maturation,
NLRP1 participates in the regulation of cell death. Zhai et al. have shown that the knocking down
of NLRP1 in human melanoma cell lines promotes apoptosis [32], suggesting that enhanced NLRP1
inflammasome activity could be associated with the tumor-promoting role of NLRP1 in cancer cells. In
addition, Kovarova et al. has shown that NLRP1-dependent pyroptosis leads to acute lung injury [33].
They showed that the lungs of Casp1−/−mice were protected from developing acute respiratory distress,
a catastrophic consequence of the NLRP1 activation, suggesting that caspase-1 activation, not only
IL-1β processing, is also the critical outcome of NLRP1 activation. In the presented study, we have
shown that NLRP1 SNP rs12150220 exhibits only a nominal association with COPD risk, demonstrated
with a p value of 0.03, which is not significant enough to pass the Bonferroni correction process.
However, odds ratio values of 0.55 suggest a potential protective effect of the tested SNP in the COPD
population. It remains to be further examined how NLRP1 genotypes could be associated with a worse
prognosis of COPD, as found in our study, and potential protective properties in COPD development.
It is possible that the presence of a mutated allele could be generally protective, but in the case of
‘double-hits’, COPD and the mutated allele could be potentially detrimental, as was shown in our
study. Nevertheless, since there is a dual role of NLRP1 activities, namely, inflammasome-mediated
IL-1b regulation and the caspase-mediated regulation of apoptosis and pyroptosis, it is very likely that
the fine-tuning of these activities, in different cells of lung parenchyma, contributes to protection.
It is also important to say that our study has several limitations. Our study, as most of the genetic
case-control studies on complex diseases, such as COPD, suffers from the heterogeneity of the tested
cohorts, and in our case, the presence of different comorbidities and smoking behaviors/statuses. COPD
is a smoking related disease, and in our study 91.8% of the COPD patients were current or former
smokers. It is very difficult to recruit a comparable control population without respiratory problems or
other comorbidities. Also, our control population consisted of healthy blood donors, and included only
25.5% current or former smokers. Finally, men dominated in the COPD population (69.2%), and among
blood donors this was even more true (87.3%). Therefore, we took these differences into account in our
analyses by adjusting for age, sex, and smoking status. Furthermore, the COPD patients represented
many different comorbidities, 54.6% had at least two comorbidities, thus creating many different
phenotypes with different level of severity of the disease. Presence of different comorbidities, especially
those associated with chronic inflammation, should be taken with special caution. Also, the size of the
tested cohorts should be significantly larger because the analyses included small subgroups, decreasing
the power to detect associations. Larger studies with well-characterized study populations are needed
to fully clarify the associations observed in our study and to investigate the functional basis of the
associations. Therefore, it is important to say that our results should be carefully interpreted. Still,
we believe that results presented here have contributed, at least in part, to the progress in elucidating
the pathogenesis of COPD, in the context of the genetic variability of the receptors of innate immune
response, like NLRPs.
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